Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyteir Therapeutics, Inc. - Common Stock (NQ:CYT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyteir Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
From Cyteir Therapeutics
Via Business Wire
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851
Cyteir Announces Halt of CYT-0851 Development and Company Dissolution Biotech firm Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced today its decision 
Via Spotlight Growth
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
From Cyteir Therapeutics
Via Business Wire
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
From Cyteir Therapeutics, Inc.
Via Business Wire
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Cyteir Therapeutics
Via Business Wire
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Names Adam Veness General Counsel
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of Directors
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.